91 related articles for article (PubMed ID: 21193210)
1. Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors.
Mitmaker EJ; Griff NJ; Grogan RH; Sarkar R; Kebebew E; Duh QY; Clark OH; Shen WT
Surgery; 2011 Apr; 149(4):504-11. PubMed ID: 21193210
[TBL] [Abstract][Full Text] [Related]
2. The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression.
Liu HB; Voso MT; Gumiero D; Duong J; McKendrick JJ; Dear AE
Int J Oncol; 2009 Feb; 34(2):573-9. PubMed ID: 19148494
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.
Shen WT; Wong TS; Chung WY; Wong MG; Kebebew E; Duh QY; Clark OH
Surgery; 2005 Dec; 138(6):979-84; discussion 984-5. PubMed ID: 16360381
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
5. Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549).
Vinodhkumar R; Song YS; Ravikumar V; Ramakrishnan G; Devaki T
Chem Biol Interact; 2007 Feb; 165(3):220-9. PubMed ID: 17240363
[TBL] [Abstract][Full Text] [Related]
6. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion.
Liu LT; Chang HC; Chiang LC; Hung WC
Cancer Res; 2003 Jun; 63(12):3069-72. PubMed ID: 12810630
[TBL] [Abstract][Full Text] [Related]
8. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate.
Kaneko F; Saito H; Saito Y; Wakabayashi K; Nakamoto N; Tada S; Suzuki H; Tsunematsu S; Kumagai N; Ishii H
Int J Oncol; 2004 Apr; 24(4):837-45. PubMed ID: 15010820
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Poli R; Bosco O; Mastrocola R; Aragno M; Boccuzzi G
J Endocrinol; 2006 Nov; 191(2):465-72. PubMed ID: 17088416
[TBL] [Abstract][Full Text] [Related]
11. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.
Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S
Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA
Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.
Dong X; Korch C; Meinkoth JL
Endocr Relat Cancer; 2011 Jun; 18(3):301-10. PubMed ID: 21367844
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.
Yoon CY; Park MJ; Lee JS; Lee SC; Oh JJ; Park H; Chung CW; Abdullajanov MM; Jeong SJ; Hong SK; Byun SS; Lee ES; Lee SE
J Urol; 2011 Mar; 185(3):1102-11. PubMed ID: 21255805
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
18. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.
Catalano MG; Pugliese M; Poli R; Bosco O; Bertieri R; Fortunati N; Boccuzzi G
Oncol Rep; 2009 Feb; 21(2):515-21. PubMed ID: 19148530
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
Mutze K; Langer R; Becker K; Ott K; Novotny A; Luber B; Hapfelmeier A; Göttlicher M; Höfler H; Keller G
Ann Surg Oncol; 2010 Dec; 17(12):3336-43. PubMed ID: 20585871
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of a benz[f]indole-4,9-dione analog on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells.
Park HJ; Lee HJ; Min HY; Chung HJ; Suh ME; Park-Choo HY; Kim C; Kim HJ; Seo EK; Lee SK
Eur J Pharmacol; 2005 Dec; 527(1-3):31-6. PubMed ID: 16309669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
